Aizon is an AI platform for pharmaceutical and biotech manufacturing, founded in 2014 by Toni Manzano, Pep Gubau, and Pere Merino under the name bigfinite before rebranding to Aizon; the company is headquartered in San Francisco with a second office in Barcelona and has raised $44.6 million over five funding rounds, most recently a Series C in February 2024.
The platform applies machine learning to GxP-regulated manufacturing data, including batch records, sensor readings, and quality data, to catch deviations before they cause a failed batch, generate audit-ready documentation, and support faster time-to-market for drug approvals. Its Aizon Predict product is available as a private offer on AWS Marketplace for pharma manufacturers and CDMOs that want to move ML models into production without building the compliance layer themselves.
Aizon is built for pharmaceutical and biotech manufacturers and contract development and manufacturing organizations operating under GxP requirements, not general industrial manufacturers. Pricing is fully custom, arranged through AWS Marketplace private includes or direct sales contact rather than published rates.
